Showing 1 - 10 of 563
We examine how two highly successful new biotechnology firms (NBFs) source their most critical input -- scientific knowledge. We find that scientists at the two NBFs enter into large numbers of collaborative research efforts with scientists at other organizations, especially universities. Formal...
Persistent link: https://www.econbiz.de/10013219302
This paper examines whether there are complementarities between investments in ICT, R&D and organizational innovation … return of 9.7%, followed by 6% to 7% on organizational innovation and a modest 1.4% to 1.8% on R&D in services and …
Persistent link: https://www.econbiz.de/10012911090
We study a firm that justifies its novel use of equity derivatives as a cash-flow hedging strategy. Our purpose is to understand the challenge of translating risk management theory into managerial action. Cephalon Inc., a biotech firm, bought a large block of call options on its own stock. If...
Persistent link: https://www.econbiz.de/10012755991
Managers of private entrepreneurial firms face obstacles in raising capital both in placing a value on a firm and conveying value to investors. These problems are exacerbated when the firm is small, has limited assets (except for human capital) and has yet to have a lead product. In such cases...
Persistent link: https://www.econbiz.de/10012749932
How does competition affect innovation and how it is financed in R&D-intensive firms? We study the interaction between …
Persistent link: https://www.econbiz.de/10013029032
We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly linking specific grant...
Persistent link: https://www.econbiz.de/10013029543
of placed-based policies designed to spur innovation clusters. We estimate that the adoption of subsidies for biotech …
Persistent link: https://www.econbiz.de/10013035236
In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an empirical analysis of 200 contracts. Consistent with...
Persistent link: https://www.econbiz.de/10013224324
Advance of science and its commercial applications are in a close, symbiotic relationship in the U.S. biotechnology industry. Comparing Japan and the U.S., the structure of the science appears broadly similar, but the organization of the biotechnology industry is quite dissimilar. In the U.S.,...
Persistent link: https://www.econbiz.de/10013230186
Using data on over 900 firms for the period 1988-2000, we estimate the effect on phase-specific biotech and pharmaceutical R&D success rates of a firm's overall experience, its experience in the relevant therapeutic category; the diversification of its experience, and alliances with large and...
Persistent link: https://www.econbiz.de/10013233843